Weekly Recap: Mimrylo approved for Polycythemia Vera and zasocitinib NDA
Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TSE:4502) scored an FDA win with Mimrylo (rusfertide) approval for polycythemia vera after Phase 3 VERIFY showed superior hematocrit control and fewer phlebotomies, while the FDA also accepted and granted Priority Review to the TAK-279 NDA for plaque ps…